Dionisio Yorro, MD
Emergency Medicine · Gurnee, ILNPI 1942245147
Payments from drug & device makers
Across 621 payments — averaging $57.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- AstraZeneca$2K
- Novo Nordisk$2K
- Boehringer Ingelheim$2K
- Sanofi-aventis U.S. LLC$859
- Lilly USA, LLC$721
- plus $4K from 18 others
Across 402 payments — averaging $787.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$317K
What the payments were for
- Consulting fees$23,85467%
- Food & beverage$11,53833%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $24,185 |
| AstraZeneca | 95 | $2,085 |
| Novo Nordisk | 110 | $1,716 |
| Boehringer Ingelheim | 84 | $1,623 |
| Sanofi-aventis U.S. LLC | 35 | $859 |
| Lilly USA, LLC | 39 | $721 |
| Amgen(2 entities) | 31 | $670 |
| Amarin Pharma, Inc. | 25 | $551 |
| Novartis | 37 | $511 |
| E.r. Squibb & Sons, L.L.C. | 25 | $439 |
| Merck | 27 | $412 |
| Esperion Therapeutics, Inc. | 15 | $376 |
| Pfizer | 12 | $365 |
| Johnson & Johnson | 15 | $273 |
| Boston Scientific | 8 | $264 |
| Abbott | 7 | $122 |
| Ascensia Diabetes Care US Inc. | 5 | $82 |
| Astellas Pharma US Inc | 3 | $60 |
| Sanofi Pasteur Inc. | 2 | $52 |
| Inspire Medical Systems, Inc. | 2 | $32 |
| Bayer | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Optinose US, Inc. | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,480 in reported general payments places this provider in the 95th percentile of 2,434 emergency medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 89 | $107,315 |
| JardianceEmpagliflozin | 56 | $83,931 |
| OzempicSemaglutide | 57 | $82,725 |
| EliquisApixaban | 50 | $76,253 |
| TrulicityDulaglutide | 21 | $49,367 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $26,551 |
| XareltoRivaroxaban | 16 | $21,772 |
| VascepaIcosapent Ethyl | 31 | $17,404 |
| LinzessLinaclotide | 12 | $9,485 |
| Atorvastatin Calcium | 466 | $4,641 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $4,339 |
| Losartan Potassium | 253 | $2,423 |
| Ezetimibe | 81 | $2,246 |
| Amlodipine Besylate | 308 | $1,626 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 127 | $1,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $2,085 | $107,31589 claims |
| Boehringer IngelheimJardiance | $1,623 | $83,93156 claims |
| Novo NordiskOzempic | $1,716 | $82,72557 claims |
| PfizerEliquis | $365 | $76,25350 claims |
| Lilly USA, LLCTrulicity | $721 | $49,36721 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $859 | $26,55114 claims |
| Johnson & JohnsonXarelto | $273 | $21,77216 claims |
| AbbVieLinzess | $24,185 | $9,48512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,434 emergency medicine providers in Illinois.
Other emergency medicine in Gurnee
- Erika ClaytonBolingbrook$837K
- Kristen FergusonSpringfield$511K
- Lois ClarkeChicago$415K
- Michael GottliebChicago$364K
- Jonathan ClaudLisle$171K
- Christopher RossChicago$132K
- Jonathan HandlerNorthbrook$113K
- Erik KulstadChicago$109K
- Philip MitchellNormal$107K
- Adam GoodcoffChicago$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.